Nasopharyngeal Cancer
Oncology·MeSH: Nasopharyngeal Neoplasms
Prevalence
11.3 / 100K
Incidence
2.2 / 100K/yr
1 drug in development·1 company·5 clinical trials
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| toripalimab | Coherus Oncology, Inc. (CHRS) |
Frequently asked questions
How many drugs are in development for Nasopharyngeal Cancer?
BioSniper tracks 1 drug in development for Nasopharyngeal Cancer across 1 company.
How many clinical trials target Nasopharyngeal Cancer?
There are 5 clinical trials targeting Nasopharyngeal Cancer tracked by BioSniper.
What is the prevalence of Nasopharyngeal Cancer?
The estimated prevalence of Nasopharyngeal Cancer is approximately 11.3 per 100,000 population.
Deep-dive into Nasopharyngeal Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis